Targeted Application of Human Genetic Variation Can Improve Red Blood Cell Production from Stem Cells

Felix C. Giani, Claudia Fiorini, Aoi Wakabayashi, Leif S. Ludwig, Rany M. Salem, Chintan D. Jobaliya, Stephanie N. Regan, Jacob C. Ulirsch, Ge Liang, Orna Steinberg-Shemer, Michael H. Guo, Tõnu Esko, Wei Tong, Carlo Brugnara, Joel N. Hirschhorn, Mitchell J. Weiss, Leonard I. Zon, Stella T. Chou, Deborah L. French, Kiran MusunuruVijay G. Sankaran*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Multipotent and pluripotent stem cells are potential sources for cell and tissue replacement therapies. For example, stem cell-derived red blood cells (RBCs) are a potential alternative to donated blood, but yield and quality remain a challenge. Here, we show that application of insight from human population genetic studies can enhance RBC production from stem cells. The SH2B3 gene encodes a negative regulator of cytokine signaling and naturally occurring loss-of-function variants in this gene increase RBC counts in vivo. Targeted suppression of SH2B3 in primary human hematopoietic stem and progenitor cells enhanced the maturation and overall yield of in-vitro-derived RBCs. Moreover, inactivation of SH2B3 by CRISPR/Cas9 genome editing in human pluripotent stem cells allowed enhanced erythroid cell expansion with preserved differentiation. Our findings therefore highlight the potential for combining human genome variation studies with genome editing approaches to improve cell and tissue production for regenerative medicine.

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalCell Stem Cell
Issue number1
StatePublished - 7 Jan 2016
Externally publishedYes


Dive into the research topics of 'Targeted Application of Human Genetic Variation Can Improve Red Blood Cell Production from Stem Cells'. Together they form a unique fingerprint.

Cite this